[Efficacy of specific sublingual immunotherapy with dermatophagoides farinae drops in the treatment of cough variant asthma in children].
OBJECTIVE
To study the efficacy and safety of specific sublingual immunotherapy with dermatophagoides farinae drops in the treatment of cough variant asthma in children.


METHODS
A total of 106 children aged 4-14 years old with cough variant asthma and positive skin prick test responses to dermatophagoides farinae allergens were randomly divided into two groups: SLIT group (n=53), which received specific sublingual immunotherapy with dermatophagoides farinae drops as well as standardized treatment and conventional treatment group (n=53), which received standardized treatment alone. Improvement in cough/asthma symptom scores and the time taken for symptoms to improve were observed after treatment. Serum eosinophil (EOS) level and peak expiratory flow (PEF) were measured after treatment. The side effects were observed.


RESULTS
Compared with the conventional treatment group, the SLIT group showed significant decrease in symptom scores and serum EOS level and significant increase in PEF (P<0.05). The time at which symptoms began to improve in the SLIT group was earlier than in the conventional treatment group (P<0.05). The effective rate in the SLIT group was significantly higher than in the conventional treatment group (85% vs 68%; P<0.05). Local reactions such as redness, swelling, and itching occurred in some children of the SLIT group but disappeared on the following day.


CONCLUSIONS
Specific sublingual immunotherapy with dermatophagoides farinae drops is an effective and highly safe treatment for cough variant asthma in children.
Bo'ai Hospital of Zhongshan City, Zhongshan, Guangdong 528403, China. 13924973891@139.com
Bo-Qiang
BQ
Zheng
Gui-Lan
GL
Wang
Sai
S
Yang
D000286:Administration, Sublingual; D000293:Adolescent; D039741:Antigens, Dermatophagoides / Q000276:immunology*; D001249:Asthma / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003371:Cough / Q000628:therapy*; D003888:Desensitization, Immunologic / Q000009:adverse effects; D004804:Eosinophils / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male
D039741:Antigens, Dermatophagoides